# EDGAR Filing Document

**Accession Number:** 0002115339
**File Stem:** 0002115339-26-000002
**Filing Date:** 2026-3
**Character Count:** 10571
**Document Hash:** 07b3c999bef232e124db57245e38610e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002115339-26-000002.hdr.sgml**: 20260327

**ACCESSION NUMBER**: 0002115339-26-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260324

**FILED AS OF DATE**: 20260327

**DATE AS OF CHANGE**: 20260327

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** PATEL DHAVALKUMAR DHIRAJLAL
- **CENTRAL INDEX KEY:** 0002115339

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39941
- **FILM NUMBER:** 26807549

**MAIL ADDRESS:**
- **STREET 1:** C/O SANA BIOTECHNOLOGY, INC.
- **STREET 2:** 100 TECHNOLOGY SQUARE, 2ND FLOOR
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sana Biotechnology, Inc.
- **CENTRAL INDEX KEY:** 0001770121
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 831381173
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 188 EAST BLAINE STREET, SUITE 350
- **CITY:** SEATTLE
- **STATE:** WA
- **BUSINESS PHONE:** (206) 701-7914

**MAIL ADDRESS:**
- **STREET 1:** 188 EAST BLAINE STREET, SUITE 350
- **CITY:** SEATTLE
- **STATE:** WA

## Ex-24

```

POWER OF ATTORNEY
With respect to holdings of and transactions in securities
issued by Sana Biotechnology, Inc. (the "Company"), the undersigned
hereby constitutes and appoints the individuals named on Schedule A
attached hereto and as may be amended from time to time, or any of
them signing singly, with full power of substitution and
resubstitution, to act as the undersigned's true and lawful
attorney-in-fact to:

1. execute for and on behalf of the undersigned, Schedules 13D
and 13G in accordance with Section 13 of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and
regulations thereunder, or under Rule 144 under the
Securities Act of 1933 ("Rule 144"),
with respect to the any security of the Company, including
Forms 3, 4, and 5 in
accordance with Section 16 of the Exchange Act and the rules
thereunder, and a Form ID, Uniform Application for Access
Codes to File on EDGAR;

2. do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete
and execute any such Schedule 13D or 13G or Form 3, 4, or 5
or Form 144,
complete and execute any amendment or amendments thereto, and
timely file such schedule or form with the SEC and any stock
exchange or similar authority; and

3. take any other action of any type whatsoever in connection
with the foregoing which, in the opinion of such attorney-in-
fact, may be of benefit to, in the best interest of, or
legally required by, the undersigned, it being understood
that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney
shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary, or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all
intents and purposes as the undersigned might or could do if
personally present, with full power of substitution and
resubstitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorneys-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this
Power of Attorney and the rights and powers herein granted.

The undersigned acknowledges that the foregoing attorneys-in-
fact, in serving in such capacity at the request of the undersigned,
are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 13 and Section
16 of the Exchange Act or Rule 144.

This Power of Attorney shall remain in full force and effect
until the undersigned is no longer required to file Schedule 13D or
13G or Forms 3, 4, or 5 and/or Form 144
with respect to the undersigned's holdings
of and transactions in securities issued by the Company, unless
earlier (a) revoked by the undersigned in a signed writing delivered
to the foregoing attorneys-in-fact or (b) superseded by a new power
of attorney regarding the purposes outlined in the first paragraph
hereof dated as of a later date.

IN WITNESS WHEREOF, the undersigned has caused this Power
of Attorney to be executed as of February 18, 2026.

/s/ Dhavalkumar Dhirajlal Patel
Dhavalkumar Dhirajlal Patel

Schedule A

Individuals Appointed as Attorney-in-Fact with Full Power of
Substitution and Resubstitution

1. Steven D. Harr
2. Brian Piper
3. Aaron M. Grossman
4. Susan D. Wyrick
5. Danielle A. Shultz

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>PATEL DHAVALKUMAR DHIRAJLAL<br><sub>(Last) (First) (Middle)</sub><br>C/O SANA BIOTECHNOLOGY, INC.<br>188 EAST BLAINE STREET, SUITE 350<br><sub>(Street)</sub><br>SEATTLE, WA 98102<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Sana Biotechnology, Inc. [ SANA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-24 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, Chief Scientific Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 99510.00 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | <sup>(1)</sup> | 2034-08-25 | Common Stock | 515000.00 | $5.84 | D |  |
| Stock Option (Right to Buy) | <sup>(2)</sup> | 2035-03-05 | Common Stock | 375000.00 | $2.55 | D |  |
| Stock Option (Right to Buy) | <sup>(3)</sup> | 2036-03-04 | Common Stock | 506250.00 | $3.41 | D |  |
| Restricted Stock Units | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 375000.00 | <sup>(4)</sup> | D |  |
| Restricted Stock Units | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 62500.00 | <sup>(4)</sup> | D |  |
| Restricted Stock Units | <sup>(7)</sup> | <sup>(7)</sup> | Common Stock | 112500.00 | <sup>(4)</sup> | D |  |

---

### Footnotes:

(1) The option vested as to 25% of the shares underlying the option on August 26, 2025 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana Biotechnology, Inc. ("Sana") as an employee, consultant, director or officer of Sana through each such date.

(2) The option vested as to 25% of the shares underlying the option on March 6, 2026 and the remainder vests in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

(3) The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

(4) Each restricted stock unit represents a contingent right to receive one share of Sana common stock.

(5) The award vested as to 25% of the restricted stock units on August 26, 2025 and the remaining restricted stock units will vest in three equal installments on each of August 26, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

(6) The award vested as to 25% of the restricted stock units on March 6, 2026 and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

(7) The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.

**Signature:** /s/ Aaron M. Grossman, Attorney-in-Fact for Dhavalkumar Dhirajlal Patel  
**Date:** 2026-03-27

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**